European Journal of Cancer
Volume 41, Issue 11 , Pages 1542-1546 , July 2005

The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC)

  • Matthew Ng

      Affiliations

    • Department of Medicine, Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, United Kingdom
    • ,
  • David Cunningham

      Affiliations

    • Department of Medicine, Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, United Kingdom
    • Corresponding Author InformationCorresponding author. Tel.: +44 208 661 3156; fax: +44 208 643 9414.
    • ,
  • Andrew R. Norman

      Affiliations

    • Department of Computing, Royal Marsden Hospital, London and Surrey, United Kingdom

Received 19 April 2004 ,Revised 21 March 2005 ,Accepted 21 March 2005.

References 

  1. Roth A, Kolaric K, Popovic S. Letter: cardiotoxicity of 5-fluorouracil (NSC-19893). Cancer Chemother Rep. 1975;59(6):1051–1052
  2. Meyer CC, Calis KA, Burke LB, et al. Symptomatic cardiotoxicity associated with 5-fluorouracil. Pharmacotherapy. 1997;17(4):729–736
  3. de Forni M, Malet-Martino MC, Jaillais P, et al. Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. J Clin Oncol. 1992;10(11):1795–1801
  4. Akhtar SS, Salim KP, Bano ZA. Symptomatic cardiotoxicity with high-dose 5-fluorouracil infusion: a prospective study. Oncology. 1993;50(6):441–444
  5. Keefe DL, Roistacher N, Pierri MK. Clinical cardiotoxicity of 5-fluorouracil. J Clin Pharmacol. 1993;33(11):1060–1070
  6. Labianca R, Beretta G, Clerici M. Cardiotoxicity of 5-flurouracil: a study of 1083 patients. Tumori. 1982;68:505–510
  7. Robben NC, Pippas AW, Moore JO. The syndrome of 5-fluorouracil cardiotoxicity. An elusive cardiopathy. Cancer. 1993;71(2):493–509
  8. Mackean M, Planting A, Twelves C, et al. Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J Clin Oncol. 1998;16(9):2977–2985
  9. Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol. 2001;19(8):2282–2292
  10. Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol. 2001;19(21):4097–4106
  11. Borner MM, Dietrich D, Stupp R, et al. Phase II study of capecitabine and oxaliplatin in first-and second-line treatment of advanced or metastatic colorectal cancer. J Clin Oncol. 2002;20(7):1759–1766
  12. Scheithauer W, Kornek GV, Raderer M, et al. Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2003;21(7):1307–1312
  13. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22(1):23–30
  14. Rothenberg ML, Oza AM, Bigelow RH, et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol. 2003;21(11):2059–2069
  15. Frickhofen N, Beck FJ, Jung B, et al. Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil. Ann Oncol. 2002;13(5):797–801
  16. Bertolini A, Flumano M, Fusco O, et al. Acute cardiotoxicity during capecitabine treatment: a case report. Tumori. 2001;87(3):200–206
  17. Van Cutsem E, Hoff PM, Blum JL, et al. Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil. Ann Oncol. 2002;13(3):484–485
  18. Shoemaker LK, Arora U, Rocha Lima CM. 5-Fluorouracil-induced coronary vasospasm. Cancer Control. 2004;11(1):46–49
  19. Sudhoff T, Enderle MD, Pahlke M, et al. 5-Fluorouracil induces arterial vasocontractions. Ann Oncol. 2004;15(4):661–664
  20. Becker K, Erckenbrecht JF, Haussinger D, et al. Cardiotoxicity of the antiproliferative compound fluorouracil. Drugs. 1999;57(4):475–484
  21. Rezkalla S, Kloner RA, Ensley J, et al. Continuous ambulatory ECG monitoring during fluorouracil therapy: a prospective study. J Clin Oncol. 1989;7(4):509–514
  22. Grandi AM, Pinotti G, Morandi E, et al. Noninvasive evaluation of cardiotoxicity of 5-fluorouracil and low doses of folinic acid: a one-year follow-up study. Ann Oncol. 1997;8(7):705–708
  23. Sasson Z, Morgan CD, Wang B, et al. 5-Fluorouracil related toxic myocarditis: case reports and pathological confirmation. Can J Cardiol. 1994;10(8):861–864
  24. Koenig H, Patel A. Biochemical basis for fluorouracil neurotoxicity. The role of Krebs cycle inhibition by fluoroacetate. Arch Neurol. 1970;23(2):155–160
  25. Haskel C. Drugs used in cancer chemotherapy. In:  Haskel CM editors. Cancer treatment. 2nd ed.. Philadelphia: Saunders; 1984;p. 43–106
  26. Kuzel T, Esparaz B, Green D, et al. Thrombogenicity of intravenous 5-fluorouracil alone or in combination with cisplatin. Cancer. 1990;65(4):885–889

PII: S0959-8049(05)00346-1

doi: 10.1016/j.ejca.2005.03.027

European Journal of Cancer
Volume 41, Issue 11 , Pages 1542-1546 , July 2005

Article Tools